肿瘤生物治疗研究和应用述评

80年代中叶以来,肿瘤生物治疗已做为重要的肿瘤治疗模式而被广泛研究和应用于临床,并取得一定疗效。但不论在基础研究与临床应用中,均有一些问题有待深入研究,以期扬长避短,发挥生物疗法在肿瘤治疗中的特点与疗效。 1 肿瘤生物治疗的演进 肿瘤生物治疗是一种既古老而又年轻的疗法。上溯千余年,在中医药中就有“扶正祛邪”、“软坚散结”、“以毒攻毒”、“活血化瘀”等利用中药来治疗癌症的治则。19世纪末叶西方提出用Coley毒素治疗癌症。现代肿瘤免疫治疗概念的建立,始于1953年动物肿瘤特异性移植抗原的发现——肿瘤免疫学的诞生。此后至1983年多种非特异性生物制剂(卡介苗、短小棒状杆菌、免疫核糖核酸、转移因子等)的大量临床应用和通过动物实验,为人类肿瘤免疫治疗奠定了科学基础。80年代中叶,伴随现代分子生物学和生物工程技术的发展,重组细胞因子的出现,第一例肿瘤病人自体CTL过继免疫治疗的问世,

The molecular mechanisms of Yang Wei Kang Liu powder on anticancer and reducing chemotherapy side-effect in combination with chemotherapy

Objective:We studied the molecular mechanisms of Yang Wei Kang Liu Power(YWKL,traditional Chinese medicine for nourishing stomach and anticancer) on anticancer and reducing chemotherapy side-effect in combination with chemotherapy.Methods:615 pre-cancer mouse model of YWKL for 10 days and CTX 1 time,semi-quantitative reverse transcription-polymerase chain reaction(RT-PCR) to detect bone marrow granulocyte-macrophage colony-stimulating factor(GM-CSF) gene and cancer proto-oncogene Bcl-2,c-myc expression.Results:YWKL in combination with chemotherapy could obviously promoted the expression of GM-CSF gene and inhibited the expression of Bcl-2 and c-myc oncogenes of FC 615 mice.Conclusion:The molecular mechanisms of anticancer and reducing chemotherapy side-effect of YWKL in combination with chemotherapy are to promote the expression of GM-CSF gene and inhibit the expression of Bcl-2 and c-myc oncogenes.